{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T19:09:02Z","timestamp":1781291342792,"version":"3.54.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Context<\/jats:title><jats:p>Germline succinate dehydrogenase subunit B (<jats:italic>SDHB<\/jats:italic>) pathogenic variants are characteristic of familial paraganglioma (PGL) syndrome type 4. This syndrome frequently presents with abdominal PGL and has high tendency for locally aggressive behavior and distant metastasis. The vast majority of pituitary adenomas (PAs) are sporadic. However, PAs can be part of a number of familial tumor syndromes such as multiple endocrine neoplasia type 1 (MEN 1) or more rarely in association with pheochromocytoma and PGL (referred to as 3P syndrome). Only a limited number of PAs in association with <jats:italic>SDHB<\/jats:italic>-related PGL has been reported and the vast majority occurred subsequently or simultaneously with pheochromocytoma\/PGL (collectively abbreviated as PPGL). In this report, we describe a young patient who had a giant pituitary macroprolactinoma resistant to large doses of cabergoline (CBG) and external beam radiotherapy (XRT). The patient did not have personal history of PPGL but was found to carry a germline <jats:italic>SDHB<\/jats:italic> pathogenic variant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case report<\/jats:title><jats:p>A 38-year-old woman presented with headache, visual disturbances and galactorrhea and was found to have a 34-mm macroprolactinoma. She was treated with CBG 3-4 mg per week but PA continued to grow and caused significant cranial pressure symptoms. She underwent two transsphenoidal surgeries with rapid tumor recurrence after each one. She received XRT but PA continued to grow. She was finally treated with temozolomide with excellent response. Whole exome and subsequent Sanger sequencing confirmed that she has a pathogenic monoallelic <jats:italic>SDHB<\/jats:italic> mutation (NM_003000:c.C343T, p.R115*). PA tissue showed loss of heterozygosity for the same mutation and absent SDHB immunostaining confirming the pathogenic role of this <jats:italic>SDHB<\/jats:italic> mutation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Germline <jats:italic>SDHB<\/jats:italic> mutations can rarely cause PA in the absence of PPGL. They should be considered as a possible cause of aggressiveness and resistance to dopamine agonists in similar cases.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1273093","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T04:48:03Z","timestamp":1702442883000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["An aggressive cabergoline-resistant, temozolomide-responsive macroprolactinoma due to a germline SDHB pathogenic variant in the absence of paraganglioma or pheochromocytoma"],"prefix":"10.3389","volume":"14","author":[{"given":"Ali S.","family":"Alzahrani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulghani","family":"Bin Nafisah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meshael","family":"Alswailem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosra","family":"Moria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmara","family":"Poprawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hindi","family":"Al-Hindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Pacak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noy131","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015","volume":"20","author":"Ostrom","year":"2018","journal-title":"Neuro Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-013-1354-5","article-title":"Epidemiology and etiopathogenesis of pituitary adenomas","volume":"117","author":"Aflorei","year":"2014","journal-title":"J Neurooncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.5444","article-title":"Diagnosis and management of pituitary adenomas: a review","volume":"329","author":"Tritos","year":"2023","journal-title":"Jama"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and treatment of pituitary adenomas: a review","volume":"317","author":"Molitch","year":"2017","journal-title":"Jama"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15660","article-title":"Dopamine agonists for the treatment of pituitary tumours: From ergot extracts to next generation therapies","volume":"89","author":"Wexler","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/eje-17-0796","article-title":"European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-023-01305-8","article-title":"Refractory lactotroph adenomas","volume":"26","author":"Urwyler","year":"2023","journal-title":"Pituitary"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-020-02180-4","article-title":"The KBTBD6\/7-DRD2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatment","volume":"140","author":"Liu","year":"2020","journal-title":"Acta Neuropathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-019-09587-0","article-title":"The genomic landscape of sporadic prolactinomas","volume":"30","author":"De Sousa","year":"2019","journal-title":"Endocr Pathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-013-1276-2","article-title":"Low levels of PRB3 mRNA are associated with dopamine-agonist resistance and tumor recurrence in prolactinomas","volume":"116","author":"Wang","year":"2014","journal-title":"J Neurooncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.mito.2010.03.001","article-title":"Succinate dehydrogenase \u2013 Assembly, regulation and role in human disease","volume":"10","author":"Rutter","year":"2010","journal-title":"Mitochondrion."},{"key":"B13","doi-asserted-by":"publisher","first-page":"R65","DOI":"10.1530\/eo-22-0044","article-title":"Pheochromocytoma and paraganglioma: germline genetics and hereditary syndromes","volume":"2","author":"Turin","year":"2022","journal-title":"Endocr Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.10235","article-title":"Familial paraganglioma and gastric stromal sarcoma: A new syndrome distinct from the Carney triad","volume":"108","author":"Carney","year":"2002","journal-title":"Am J Med Genet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1530\/erc-11-0324","article-title":"Biallelic inactivation of the SDHC gene in renal carcinoma associated with paraganglioma syndrome type 3","volume":"19","author":"Malinoc","year":"2012","journal-title":"Endocrine-Related Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2689","article-title":"Succinate dehydrogenase (SDH)-deficient pancreatic neuroendocrine tumor expands the SDH-related tumor spectrum","volume":"100","author":"Niemeijer","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-014-9725-4","article-title":"Exploring the association of succinate dehydrogenase complex mutations with lymphoid Malignancies","volume":"13","author":"Renella","year":"2014","journal-title":"Familial Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"R157","DOI":"10.1530\/erc-22-0157","article-title":"Succinate dehydrogenase and MYC-associated factor X mutations in pituitary neuroendocrine tumours","volume":"29","author":"Loughrey","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvac076","article-title":"Papillary thyroid cancer and a TERT promotor mutation-positive paraganglioma in a patient with a germline SDHB mutation","volume":"6","author":"Alzahrani","year":"2022","journal-title":"J Endocr Soc"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-017-2397-3","article-title":"SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations","volume":"143","author":"Jochmanova","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2019.08.005","article-title":"3P association (3PAs): Pituitary adenoma and pheochromocytoma\/paraganglioma. A heterogeneous clinical syndrome associated with different gene mutations","volume":"69","author":"Guerrero-P\u00e9rez","year":"2019","journal-title":"Eur J Intern Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3399","article-title":"Heterogeneous genetic background of the association of pheochromocytoma\/paraganglioma and pituitary adenoma: results from a large patient cohort","volume":"100","author":"D\u00e9nes","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-4297","article-title":"Pituitary adenoma with paraganglioma\/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice","volume":"100","author":"Xekouki","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-017-9474-7","article-title":"Pituitary carcinoma in a patient with an SDHB mutation","volume":"28","author":"Tufton","year":"2017","journal-title":"Endocr Pathol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.700007","article-title":"Clinical efficacy of temozolomide and its predictors in aggressive pituitary tumors and pituitary carcinomas: a systematic review and meta-analysis [Systematic review]","volume":"12","author":"Luo","year":"2021","journal-title":"Front Neurology"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1273093\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T04:48:04Z","timestamp":1702442884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1273093\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,13]]},"references-count":25,"alternative-id":["10.3389\/fendo.2023.1273093"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1273093","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,13]]},"article-number":"1273093"}}